NCT06936644View on ClinicalTrials.gov

A Multicenter, Single-arm Phase II Study to Evaluate the Efficacy and Safety of Fulzerasib (IBI351) in Combination With Ivonescimab (AK-112) in First-line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer Patients With KRAS G12C Mutation

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 30, 2025

Primary Completion Date

April 30, 2027

Study Completion Date

March 30, 2028

Conditions

KRAS G12C Lung Cancer

Interventions

DRUG

IBI351+AK112

The advanced or metastatic non-small cell lung cancer patients with KRAS G12C mutation will receive the combination of fulzerasib (IBI351) with ivonescimab (AK-112) in first-line treatment